Fig. 4: Expression of miR-126 enhances MYC activity through downregulating SPRED1, PLK2, and activating the ERK-MYC axis in CM-AML. | Nature Communications

Fig. 4: Expression of miR-126 enhances MYC activity through downregulating SPRED1, PLK2, and activating the ERK-MYC axis in CM-AML.

From: Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance

Fig. 4

a Relative expression levels Spred1 (CM vs. Ctrl p = 0.015; CM/miR-126Δ/Δ vs. Ctrl p = 0.0022; CM vs. CM/miR-126Δ/Δ p = 0.0035) and Plk2 (CM vs. Ctrl p = 0.0002; CM vs. CM/miR-126Δ/Δ p = 0.0042) normalized to level of B2m in Ctrl (black), CM (red) and CM/miR-126Δ/Δ (blue) preleukemic LSK. b Representative immunostaining of p-MYC (S62; magenta) and p-ERK (cyan) in control and CM AML LSK (left; scale bar 10 μm); western blot of SPRED1, PLK2, p-ERK, p-MYC (S62), and MYC in control and CM AML lineage-negative (Lin−) BM cells (right). c Western blot of SPRED1, PLK2, p-ERK, p-MYC (S62) and MYC in CM vs. CM/miR-126Δ/Δ Lin- BM cells. d Relative expression in CM-AML cells expressing shCtrl (black) vs. shmiR-126 (red) for miR-126 (p = 0.0018) and Spred1 (p = 0.0028) normalized to snoRNA234 and B2m, respectively (left); western blot of SPRED1, p-ERK, p-MYC (S62), and MYC (right) 2 days after transduction with shCtrl or shmiR-126 (right). e Relative expression levels of E2f1 (p = 0.0072), Cdk4 (p = 0.0136), Npm1 (p = 0.0041) normalized to level of B2m in shCtrl (black) or shmiR-126 (red) expressing CM-AML cells. Each dot represents data from an individual mouse and presented as the mean ± SEM in a; data in d, e are presented as the mean ± SD and statistical significance for all comparisons shown was determined using two-tailed T tests (*p < 0.05; **p < 0.01; ***p < 0.001); representative results of two independent experiments with similar results are shown in b, c.

Back to article page